Photo illustration: STAT; Photo: Adobe

STAT+ | Experts worry FDA’s credibility is being shredded by scandal and ‘soap opera’

Lawsuit against Tidmarsh latest blow to agency whose credibility has been shredded by infighting, regulatory uncertainty. "Nothing less than a clown show."

By Matthew Herper and Lizzy Lawrence

STAT+ | Trump administration nears deals for cheaper weight loss drugs with Novo Nordisk, Eli Lilly

Trump drug price negotiations expected to include Medicare coverage for weight loss drugs Wegovy, Zepbound, and prices as low as $150

By Daniel Payne, Elaine Chen, and Chelsea Cirruzzo

STAT+ | Microdosing aims to extend the lifespan of the GLP-1 compounding market

Telehealth company claims aside, physicians and researchers say there is no robust clinical evidence that semaglutide or tirzepatide are effective at small doses.

By Katie Palmer

Adobe/Getty Images

STAT+ | Bidding war between Pfizer, Novo Nordisk for obesity startup Metsera escalates

The higher of the two bids, from the Danish drugmaker, would value the obesity biotech at up to $10 billion.

By Elaine Chen

Opinion: A miracle pill for Parkinson’s is 50 years old. Why can’t most of the world get it?

Parkinson's has doubled globally in 25 years but access to a miracle drug is spotty. A STAT First Opinion says this is more than a supply chain problem.

By Michael S. Okun and Ray Dorsey

STAT+ | Sarepta Therapeutics’ dismal quarter marred by drug failures and a long list of excuses

A long-delayed confirmatory clinical trial fails to show a benefit for patients, and sales of the company's Elevidys gene therapy were lower.

By Adam Feuerstein

Hulton Archive/Getty Images

Opinion: I’m a neuroscientist who works on memory manipulation. My work helps me recover from addiction

A neuroscientist used his understanding of the brain’s constant change to teach it to crave human connection instead of alcohol.

By Steve Ramirez

STAT+ | Children’s hospital lobby shifts strategy amid MAHA’s rise in Washington

The Children's Hospital Association is expanding its lobbying focus to champion children's health more broadly. The shift tracks with MAHA movement trends.

By Daniel Payne